RAD001 Shows Promise In Tough-to-Treat Breast Cancer Patients

News — By on December 13, 2008 at 1:00 am

SAN ANTONIO – Investigators are reporting favorable early results using RAD001 (Afinitor) combined with weekly paclitaxel and trastuzumab to treat patients with HER-2 overexpressing metastatic breast cancer who have demonstrated prior resistance to trastuzumab. The results, released here at the 2008 San Antonio Breast Cancer Symposium (SABCS), show that RAD001 combined with trastuzumab and chemotherapy halted tumor growth in 77 percent of patients.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback